GlobeNewsWire
02 Sept 2026, 12:43 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
3 claims · each scored for market impact
AIM ImmunoTech has secured patent protection in the UK and major European markets for using Ampligen to treat Long COVID through June 2041. — Securing long-term IP exclusivity in major markets for a high-interest condition like Long COVID significantly increases the potential future valuation and licensing opportunities for the asset.
+0.60The company recently received a U.S. patent for using Ampligen in combination with pembrolizumab for cancer treatment. — Expanding the patent estate into oncology combinations increases the therapeutic versatility of the drug and opens higher-value market segments.
+0.50The European patent for Long COVID was finalized after a nine-month opposition period closed on August 25, 2026, with no oppositions filed. — The lack of opposition reduces the immediate legal risk of the patent being overturned, providing more certainty to investors.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company expanded its global patent estate for Ampligen in Europe and the UK and received a US patent for cancer treatment.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
13h ago
